Dmitry Balyasny’s BioAtla BCAB Stock Holding History

Dmitry Balyasny’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-469	Closed	-$194K	–	2651
2022 Q4	$194K	Buy	+469	New	+$195K	﹤0.01%	2140

Other funds holding BCAB

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dmitry Balyasny's BCAB Position: Q1 2023 in Review

Dmitry Balyasny sold out of BioAtla (BCAB) in Q1 2023, closing a stake of 469 shares — an estimated $194K sold.

Dmitry Balyasny first reported a position in BCAB in Q4 2022 and held it in 1 quarter. The position peaked at $194K in Q4 2022. 79 funds tracked by Wall St. Rank hold BCAB as of Q1 2023.

Dmitry Balyasny reported no remaining BioAtla position as of Q1 2023 after selling out during the quarter.
Dmitry Balyasny sold 469 BioAtla shares in Q1 2023, an estimated $194K.
Dmitry Balyasny first reported a position in BioAtla in Q4 2022 and held it in 1 quarter.
Dmitry Balyasny's BioAtla position peaked at $194K in Q4 2022.
79 funds tracked by Wall St. Rank held BioAtla as of Q1 2023.

Based on Balyasny Asset Management's 13F filing for Q1 2023, filed 15 May 2023.